Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

558
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
558
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

500
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
500
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

110
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
110
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

170
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
170

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reconfigurable metasurface enabled by ferroelectric superdomain for AI-driven shape completion.

Optics express·2026
Same author

Feasibility of target current pulse counting method for output dose measurement on the trilogy accelerator: dose quasi-quantization and real-time monitoring.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2026
Same author

Transformable "Bullet Train"-like Nanomotors for Sequentially Overcoming Tumor Delivery Barriers.

Nano letters·2025
Same author

Rod-Shaped Nanotherapeutics Alleviate Rheumatoid Arthritis by Precisely Disrupting Platelet-Mediated Pathological Crosstalk via a Morphology-Dependent Manner.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Faricimab for retinal vein occlusion: a review of current evidence and future perspectives.

Frontiers in pharmacology·2025
Same author

Blue-Light Activated Eu<sup>2+</sup>-Doped Green Ultra-Stable Persistent Luminescence Material for Emergency Lighting.

Luminescence : the journal of biological and chemical luminescence·2025

Related Experiment Video

Updated: Jul 20, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

286

Injectable Bioadhesive Hydrogels Scavenging ROS and Restoring Mucosal Barrier for Enhanced Ulcerative Colitis

Daming Li1, Jiao Li1, Tao Chen1

  • 1Key Laboratory of Advanced Technologies of Materials, Ministry of Education and School of Materials Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.

ACS Applied Materials & Interfaces
|August 2, 2023
PubMed
Summary

This study developed a novel rectal hydrogel for ulcerative colitis (UC) treatment. The hydrogel repairs the mucosal barrier and scavenges reactive oxygen species (ROS) for improved UC remission.

Keywords:
bioadhesive hydrogeldrug deliverymucosal barrierreactive oxygen speciessodium feruliculcerative colitis

More Related Videos

An Injectable and Drug-loaded Supramolecular Hydrogel for Local Catheter Injection into the Pig Heart
10:28

An Injectable and Drug-loaded Supramolecular Hydrogel for Local Catheter Injection into the Pig Heart

Published on: June 7, 2015

17.4K
Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
09:39

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications

Published on: February 7, 2021

7.9K

Related Experiment Videos

Last Updated: Jul 20, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

286
An Injectable and Drug-loaded Supramolecular Hydrogel for Local Catheter Injection into the Pig Heart
10:28

An Injectable and Drug-loaded Supramolecular Hydrogel for Local Catheter Injection into the Pig Heart

Published on: June 7, 2015

17.4K
Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
09:39

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications

Published on: February 7, 2021

7.9K

Area of Science:

  • Biomaterials Science
  • Gastroenterology
  • Drug Delivery Systems

Background:

  • Ulcerative colitis (UC) therapy struggles with achieving long-term remission.
  • Key UC pathologies include impaired mucosal barriers and inflammation.
  • A dual approach targeting barrier repair and inflammation control is needed.

Purpose of the Study:

  • To design a rectal bioadhesive hydrogel for sustained drug delivery in UC.
  • To simultaneously restore the intestinal barrier and scavenge reactive oxygen species (ROS).
  • To improve long-term remission rates in ulcerative colitis patients.

Main Methods:

  • Developed a bioadhesive hydrogel from sulfhydryl chondroitin sulfate and polydopamine (CS-PDA).
  • Incorporated sodium ferulic (SF), a ROS scavenger, into the CS-PDA hydrogel.
  • Evaluated rectal administration for prolonged retention and sustained SF release.

Main Results:

  • The CS-PDA hydrogel demonstrated mucosa-adhesive properties for extended colonic retention.
  • Sustained release of SF effectively scavenged ROS in inflamed areas.
  • Chondroitin sulfate (CS) promoted the restoration of the intestinal epithelial barrier.

Conclusions:

  • The SF-loaded CS-PDA hydrogel offers a dual-action strategy for UC treatment.
  • This approach simultaneously addresses mucosal barrier defects and oxidative stress.
  • The developed hydrogel shows promise for effective and sustained ulcerative colitis management.